as of 11-20-2026 3:45pm EST
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | ALHAMBRA |
| Market Cap: | 1.9B | IPO Year: | 2015 |
| Target Price: | $51.89 | AVG Volume (30 days): | 326.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.95 | EPS Growth: | -48.89 |
| 52 Week Low/High: | $18.08 - $51.60 | Next Earning Date: | 11-05-2026 |
| Revenue: | $519,907,752 | Revenue Growth: | 45.90% |
| Revenue Growth (this year): | 24.87% | Revenue Growth (next year): | 9.94% |
| P/E Ratio: | 30.21 | Index: | |
| Free Cash Flow: | 104.5M | FCF Growth: | +2.53% |
SEC 8-K filings with transcript text
Nov 5, 2026 · 100% conf.
1D
-15.04%
$33.70
Act: -12.66%
5D
-20.08%
$31.70
20D
-19.13%
$32.08
2 tm2629047d1_ex99-1.htm
Exhibit 99.1
Astrana Health, Inc. Reports Third Quarter 2026 Results
Company to Host Conference Call on Thursday, November 5, 2026, at 2:30 p.m. PT/5:30 p.m. ET
·Reports record revenue of $1,023.6 million, up 7% year-over-year, net income of $20.3 million, up 1,782% year-over-year, and record adjusted EBITDA(1) of $77.2 million, up 13% year-over-year for the three months ended September 30, 2026
·Reports net cash provided by operating activities of $117.1 million and free cash flow(2) of $105.4 million for the nine months ended September 30, 2026
ALHAMBRA, Calif., November 5, 2026 /PRNewswire/ -- Astrana Health, Inc. (“Astrana,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: ASTH), a physician-centric, technology-enabled healthcare company empowering providers to deliver accessible, high-quality, and high-value care to all, today announced its consolidated financial results for the third quarter ended September 30, 2026.
“Our third quarter results demonstrate the growing impact of Astrana’s physician-centric, AI-native healthcare operating platform and our team’s continued focus on execution,” said Brandon Sim, President and Chief Executive Officer of Astrana Health. “We delivered record revenue, record adjusted EBITDA, and double-digit organic earnings growth while continuing to invest in the next phase of our growth. By combining proprietary technology, aligned physician partnerships, and integrated care delivery, we’re building a scalable, repeatable model to improve patient outcomes and manage the total cost of care – a value proposition that extends across payer and reimbursement models and positions us to create sustainable long-term value for patients, physician partners, and shareholders.”
Financial Highlights for Third Quarter Ended September 30, 2026:
All comparisons are to the three months ended September 30, 2025 unless otherwise stated.
·Total revenue of $1,023.6 million, up 7% from $956.0 million
·Care Partners revenue of $968.8 million, up 8% from $897.7 million
·Net income attributable to Astrana of $13.0 million, up from $0.4 million
·Earnings per share (“EPS”) - diluted of $0.26, up from $0.01
·Adjusted EBITDA(1) of $77.2 million, up 13% from $68.5 million
·Adjusted EPS - diluted(3) of $0.71, up 4% from $0.68
Financial Highlights for Nine Months Ended September 30, 2026:
All comparisons are to the nine months ended September 30, 2025 unless otherwise stated.
·Total revenue of $2,961.2 million, up 33% from $2,231.2 million
·Care Partners revenue of $2,811.3 million, up 32% from $2,130.1 million
·Net income attributable to Astrana of $47.1 million, up 186% from $16.5 million
- diluted of $0.95, up 188% from $0.33
·Adjusted EBITDA(1) of $212.4 million, up 39% from $153.0 million
·Adjusted EPS - diluted(3) of $2.25, up 36% from $1.66
·Net cash provided by operating activities of $117.1 million
·Free cash flow(2) of $105.4 million
(1)See “Reconciliation of Net Income to EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin” and “Use of Non-GAAP Financial Measures” below for additional information.
(2)See reconciliation provided with the condensed consolidated statements of cash flows and “Use of Non-GAAP Financial Measures” below for additional information.
(3)See “Reconciliation of Net Income to Adjusted Net Income Attributable to Astrana and Adjusted EPS - Diluted” and “Use of Non-GAAP Financial Measures” below for additional information.
Recent Operating Highlights
·Closed the acquisition of an independent practice association in Georgia on October 1, 2026.
·Added two Care Enablement clients, a provider group in Connecticut and a hospital in California, with both expected to onboard onto Astrana's AI-powered technology and managed services platform in early 2027.
·Entered into several new Medicare Advantage payer partnerships effective January 1, 2027, with new health plan partners in markets including Southern California, Texas, and Arizona, supporting continued membership growth across the Astrana platform.
Segment Results for three months ended September 30, 2026:
All comparisons are to the three months ended September 30, 2025 unless otherwise stated.
Three Months Ended September 30, 2026
(in thousands) Care Partners Care Delivery Care Enablement Intersegment Elimination Corporate Costs Consolidated Total
Total revenues $968,757 $91,017 $92,001 $(128,159) $— $1,023,616
% change vs. prior year quarter 8% 5% 5%
Cost of services 829,490 69,116 47,915 (46,453) — 900,068
General and administrative expenses 77,694 22,229 18,425 (81,713) 31,412 68,047
Depreciation and amortization 12,480 1,263 1,226 — 653 15,622
Total expenses 919,664 92,608 67,566 (128,166) 32,065 983,737
Income (loss) from operations $49,093 $(1,591) $24,435 $7(1) $(32,065) $39,879
% change vs. prior year quarter 94% 56% 4%
(1)Income from operations for the intersegment elimination represents suble
Aug 6, 2026 · 100% conf.
1D
+8.04%
$36.88
Act: +4.78%
5D
+9.60%
$37.41
Act: +10.72%
20D
+9.59%
$37.40
2 tm2622348d1_ex99-1.htm
Exhibit 99.1
Astrana Health, Inc. Reports Second Quarter 2026 Results
Company to Host Conference Call on Thursday, August 6, 2026, at 2:30 p.m. PT/5:30 p.m. ET
·Reports revenue of $972.5 million, up 49% year-over-year, net income of $18.5 million, up 81% year-over-year, and adjusted EBITDA(1) of $68.9 million, up 43% year-over-year for the three months ended June 30, 2026
·Reports net cash provided by operating activities of $100.8 million and free cash flow(2) of $92.9 million for the six months ended June 30, 2026
ALHAMBRA, Calif., August 6, 2026 /PRNewswire/ -- Astrana Health, Inc. (“Astrana,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: ASTH), a physician-centric, technology-enabled healthcare company empowering providers to deliver accessible, high-quality, and high-value care to all, today announced its consolidated financial results for the second quarter ended June 30, 2026.
“Our second quarter results reflect the strength of Astrana’s physician-centric, AI-native healthcare operating system and the disciplined execution of our team,” said Brandon Sim, President and Chief Executive Officer of Astrana Health. “We continue to see accelerating demand from both providers and payers for our platform, driving strong growth, record-high adjusted diluted EPS, and robust free cash flow generation. Our performance gives us the confidence to raise our adjusted EBITDA guidance for 2026 even as we reinvest a substantial portion of our first-half outperformance into attractive growth opportunities that we believe will further strengthen our earnings power over time.”
Financial Highlights for Second Quarter Ended June 30, 2026:
All comparisons are to the three months ended June 30, 2025 unless otherwise stated.
·Total revenue of $972.5 million, up 49% from $654.8 million
·Care Partners revenue of $932.8 million, up 48% from $631.4 million
·Net income attributable to Astrana of $19.7 million, up 109% from $9.4 million
·Earnings per share (“EPS”) - diluted of $0.40, up 111% from $0.19
·Adjusted EBITDA(1) of $68.9 million, up 43% from $48.1 million
·Adjusted EPS - diluted(3) of $0.80, up 45% from $0.55
Financial Highlights for Six Months Ended June 30, 2026:
All comparisons are to the six months ended June 30, 2025 unless otherwise stated.
·Total revenue of $1,937.6 million, up 52% from $1,275.2 million
·Care Partners revenue of $1,842.5 million, up 50% from $1,232.4 million
·Net income attributable to Astrana of $34.2 million, up 112% from $16.1 million
·EPS - diluted of $0.69, up 109% from $0.33
·Adjusted EBITDA(1) of $135.2 million, up 60% from $84.5 million
·Adjusted EPS - diluted(3) of $1.54, up 59% from $0.97
·Net cash provided by operating activities of $100.8 million
·Free cash flow(2) of $92.9 million
(1)See “Reconciliation of Net Income to EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin” and “Use of Non-GAAP Financial Measures” below for additional information.
(2)See reconciliation provided with the condensed consolidated statements of cash flow and “Use of Non-GAAP Financial Measures” below for additional information.
(3)See “Reconciliation of Net Income to Adjusted Net Income Attributable to Astrana and Adjusted EPS - Diluted” and “Use of Non-GAAP Financial Measures” below for additional information.
Recent Operating Highlights
·Daniel Rothman joined as President of Physician Enterprise and Vishal Gupta joined as Senior Vice President of Enterprise Transformation, further strengthening the executive leadership team as the Company continues to scale its physician-centric, AI-native operating platform for value-based care.
·Astrana’s affiliated Accountable Care Organizations (“ACOs”) generated $120.4 million in gross shared savings for the 2024 performance year, and Astrana Care Partners ACO ranked seventh nationwide in net shared savings per beneficiary in its first performance year.
·Astrana continued to expand its Medicare Advantage footprint, including new agreements in Hawaii and Texas. The Texas agreement added approximately 3,000 new Medicare Advantage professional-risk lives.
Segment Results for three months ended June 30, 2026:
All comparisons are to the three months ended June 30, 2025 unless otherwise stated.
Three Months Ended June 30, 2026
(in thousands) Care Partners Care Delivery Care Enablement Intersegment Elimination Corporate Costs Consolidated Total
Total revenues $932,836 $74,696 $85,598 $(120,610) $— $972,520
% change vs. prior year quarter 48% 95% 109%
Cost of services 805,469 61,923 51,665 (50,559) — 868,498
General and administrative expenses 72,133 14,552 16,158 (70,091) 21,398 54,150
Depreciation and amortization 12,362 1,188 1,378 — 622 15,550
Total expenses 889,964 77,663 69,201 (120,650) 22,020 938,198
Income (loss) from operations $42,872 $(2,967) $16,397 $40(1) $(22,020) $34,322
% change vs. prior year quarter (14)% (238)% *
* Percentage change
May 7, 2026 · 100% conf.
1D
+8.01%
$38.97
Act: +8.22%
5D
+9.81%
$39.62
Act: +8.54%
20D
+10.45%
$39.85
Act: +5.29%
2 tm2613886d1_ex99-1.htm
Exhibit 99.1
Astrana Health, Inc. Reports First Quarter 2026 Results
Company to Host Conference Call on Thursday, May 7, 2026, at 2:30 p.m. PT/5:30 p.m. ET
·Reports total revenue of $965.1 million, up 56% year over year
·Reports adjusted EBITDA(1) of $66.3 million, up 82% year over year and free cash flow(2) of $64.1 million, up 372% year over year
ALHAMBRA, Calif., May 7, 2026 /PRNewswire/ -- Astrana Health, Inc. (“Astrana,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: ASTH), a physician-centric, technology-enabled healthcare company empowering providers to deliver accessible, high-quality, and high-value care to all, today announced its consolidated financial results for the first quarter ended March 31, 2026.
“We had a strong start to 2026, delivering disciplined growth, strong medical cost performance, continued operating leverage, and early performance from new full-risk contracts in line with our expectations,” said Brandon Sim, President and Chief Executive Officer of Astrana Health. “In an increasingly dynamic healthcare environment, we believe advantage will accrue to organizations that can integrate care delivery, data, and financial accountability into a single operating system. Astrana has built exactly that: a proprietary healthcare operating platform that enables us to embed AI and workflow orchestration directly into clinical and operational workflows across the enterprise. Combined with our longitudinal patient relationships and data continuity, our infrastructure allows us to translate AI into durable clinical and economic value while continuing to improve patient outcomes, operating efficiency, and scalability. We believe Astrana is well positioned to continue widening that advantage over time.”
Financial Highlights for First Quarter Ended March 31, 2026:
All comparisons are to the three months ended March 31, 2025 unless otherwise stated.
·Total revenue of $965.1 million, up 56% from $620.4 million
·Care Partners revenue of $909.7 million, up 51% from $601.0 million
·Net income attributable to Astrana of $14.4 million, up 116% from $6.7 million
·Earnings per share (“EPS”) - diluted of $0.29, up 107% from $0.14
·Adjusted EBITDA(1) of $66.3 million, up 82% from $36.4 million
·Adjusted EPS - diluted(3) of $0.74, up 76% from $0.42
·Net cash provided by operating activities of $68.1 million, up 309% from $16.6 million
·Free cash flow(2) of $64.1 million, up 372% from $13.6 million
(1) See “Reconciliation of Net Income to EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin” and “Use of Non-GAAP Financial Measures” below for additional information.
(2) See reconciliation provided with the condensed consolidated statements of cash flow and “Use of Non-GAAP Financial Measures” below for additional information.
(3) See “Reconciliation of Net Income to Adjusted Net Income Attributable to Astrana and Adjusted EPS - Diluted” and “Use of Non-GAAP Financial Measures” below for additional information.
Recent Operating Highlights
·Delivered on its commitment to convert key contracts to full-risk arrangements, with approximately 80% of Care Partners capitation revenue and approximately 40% of consolidated membership now in full-risk arrangements.
·Launched Astrana’s delegated full-risk model with a payer partner in Texas, expanding Medicare Advantage membership in the market to more than 14,000 members.
·Continued deleveraging ahead of schedule, with net leverage declining to approximately 2.3x on a pro forma trailing twelve-month basis and to 2.2x based on the midpoint of the Company’s full-year guidance.
·Foothill Regional Medical Center (“FRMC”) received Healthgrades’ 2026 Patient Safety Excellence Award™ for the fourth consecutive year and was named among Healthgrades’ America’s 100 Best Hospitals for Joint Replacement in 2026. FRMC also received the Healthgrades Joint Replacement Excellence Award for the second consecutive year, reflecting continued strength in clinical quality and patient outcomes.
Segment Results for three months ended March 31, 2026:
All comparisons are to the three months ended March 31, 2025 unless otherwise stated.
Three Months Ended March 31, 2026
(in thousands)
Care
Partners
Care
Delivery
Care
Enablement
Intersegment
Elimination
Corporate
Costs
Consolidated
Total
Total revenues
$ 909,703
$ 85,077
$ 87,745
$ (117,425 )
$ —
$ 965,100
% change vs. prior year quarter
51 %
155 %
122 %
Cost of services
785,531
72,544
48,704
(47,423 )
—
859,356
General and administrative expenses
72,546
14,374
17,259
(69,974 )
27,532
61,737
Depreciation and amortization
12,170
1,122
1,629
—
558
15,479
Total expenses
870,247
88,040
67,592
(117,397 )
28,090
936,572
Income (loss) from operations
$ 39,456
$ (2,963 )
$ 20,153
$ (28 )(1)
$ (28,090 )
$ 28,528
% change vs. prior year quarter
(11 )%
(
See how ASTH stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "ASTH Astrana Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.